Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
22 participants
INTERVENTIONAL
2016-04-30
2017-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Brain Blood Flow During Induced Hypercapnia (Excess Blood Carbon Dioxide)
NCT00001845
Brain Blood Vessel Responses to Changes in Blood Flow
NCT06629077
Brain Blood Vessel Responses to Changes in Blood Flow: Younger Cohort
NCT06629090
Non-Invasive Mapping of Cerebral Autoregulation Using Near Infrared Spectroscopy
NCT05433129
Brain Blood Flow Responses During Exercise
NCT05864950
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
SUPPORTIVE_CARE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Shock lower Mean Arterial Pressure (MAP)
Vasopressor-dependent treated to lower MAP (65 mmHg)
Lower doses of vasopressor therapy for a MAP of 65 mmHg
Propofol for light sedation
Propofol for light sedation
Shock higher MAP
Vasopressor-dependent treated to higher MAP (75 mmHg)
Higher doses of vasopressor therapy for a MAP of 75 mmHg
Propofol for light sedation
Propofol for light sedation
Healthy participant awake
Healthy participant awake
No interventions assigned to this group
Healthy participant sedated
Healthy participant Under light sedation
Propofol for light sedation
Propofol for light sedation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Higher doses of vasopressor therapy for a MAP of 75 mmHg
Lower doses of vasopressor therapy for a MAP of 65 mmHg
Propofol for light sedation
Propofol for light sedation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* being over 18 years old
* being hospitalized to the medical intensive care unit of the CHUS Fleurimont
* being in a stabilized shock state, primarily of distributive etiology
* having received an appropriate fluid resuscitation, as judged by the attending physician
Exclusion Criteria
* having a contraindication to MRI
* having a contraindication to receive light sedation with propofol
* suffering of claustrophobia or of anxiety disorder
Shock Subjects :
* having a different primary etiology of shock than distributive (cardiogenic, hypovolemic, obstructive)
* needing vasopressor therapy as the result of extracorporeal circulation
* having known cerebral lesions
* having an intra-aortic balloon pump
* being in a palliative or near end-of-life situation
* having a contraindication to MRI
* suffering of claustrophobia or of anxiety disorder
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
François Lamontagne
Clinician Scientist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
François Lamontagne
Role: PRINCIPAL_INVESTIGATOR
Université de Sherbrooke
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Université de Sherbrooke
Sherbrooke, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-1267
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.